Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $447,600.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of Akero Therapeutics stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.76, for a total transaction of $447,600.00. Following the transaction, the insider now directly owns 95,034 shares of the company’s stock, valued at approximately $4,253,721.84. This trade represents a 9.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Wednesday, March 12th, Catriona Yale sold 614 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total transaction of $27,556.32.
• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $49.87, for a total transaction of $498,700.00.

Akero Therapeutics Stock Performance

Shares of AKRO stock traded down $1.29 during trading hours on Tuesday, reaching $43.53. The company had a trading volume of 770,345 shares, compared to its average volume of 812,716. The business has a fifty day moving average price of $42.44 and a 200-day moving average price of $34.02. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40. The firm has a market cap of $3.47 billion, a PE ratio of -11.61 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01). Sell-side analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on AKRO. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Citigroup lifted their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. HC Wainwright lifted their price target on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, Canaccord Genuity Group raised their price objective on shares of Akero Therapeutics from $56.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics has a consensus rating of “Buy” and a consensus target price of $76.29.

Institutional Trading of Akero Therapeutics

Large investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in shares of Akero Therapeutics in the fourth quarter worth approximately $41,000. Sterling Capital Management LLC grew its stake in shares of Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock worth $50,000 after acquiring an additional 1,582 shares during the period. Quarry LP bought a new stake in Akero Therapeutics during the fourth quarter valued at approximately $83,000. Summit Investment Advisors Inc. grew its position in Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after buying an additional 450 shares during the period. Finally, Summit Financial Wealth Advisors LLC bought a new stake in Akero Therapeutics during the third quarter valued at approximately $205,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.